Related Experiment Video
Updated: May 27, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Krzysztof Giannopoulos1, Daniel Mertens, Stephan Stilgenbauer
1Medical University of Lublin, Experimental Hematooncology Department, Lublin, Poland.
Expert Opinion on Pharmacotherapy
|November 22, 2011
Summary
Immunomodulatory drugs like thalidomide and lenalidomide show promise in treating chronic lymphocytic leukemia (CLL). These agents offer both anti-tumor effects and immune system support, improving patient outcomes.
Area of Science:
- Oncology
- Immunology
Background:
- Chronic lymphocytic leukemia (CLL) exhibits significant biological and clinical heterogeneity.
- Immunosuppression is a common complication in CLL, impacting patient quality of life and survival.
- Effective CLL treatments should reduce tumor burden and enhance immune function.
Purpose of the Study:
- To review biological and clinical data on thalidomide and lenalidomide in CLL.
- To evaluate the efficacy and safety of these immunomodulatory drugs in CLL treatment.
Main Methods:
- Literature review of biological and clinical data.
- Analysis of thalidomide and lenalidomide mechanisms of action in CLL.
Main Results:
- Thalidomide and lenalidomide demonstrate antitumor activity and immunostimulation in CLL.
- These drugs exhibit anti-angiogenic, immunomodulatory, and tumoricidal effects.
- Effective as monotherapy and in combination regimens for CLL.
Conclusions:
- Immunomodulatory drugs are valuable therapeutic options for CLL.
- Mechanisms include anti-angiogenesis, immune modulation, and tumoricidal effects.
- Manageable toxicities with dose titration allow for effective use in CLL patients.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...